The shares of Biogen (NASDAQ:BIIB) traded with a loss of -1.87 points or -0.79% in the most recent session. The shares last traded at $235.52. As per the trading info, the shares saw $37.58 million in upticks and lost $36.39 million in downticks, resulting in a net money flow of $1.19 million. The up/down ratio for the day was measured at 1.03. For the week, the shares had posted -1.13%.From the block trade data available, the total upticks were valued at $8.52 million and the total downticks were valued at $7.09 million, thereby putting the up/down ratio at 1.2. The net money flow for the block transaction was $1.43 million.
The stock has recorded a 20-day Moving Average of 11.66% and the 50-Day Moving Average is 12.96%. The company shares have dropped 42.97% in the past 52 Weeks. On June 23, 2015 The shares registered one year high of $420.99 and one year low was seen on June 16, 2016 at $236.54. The 50-day moving average is $264.73 and the 200 day moving average is recorded at $269.95. S&P 500 has rallied 1.93% during the last 52-weeks.
Biogen (NASDAQ:BIIB): The stock opened at $238.00 on Tuesday but the bulls could not build on the opening and the stock topped out at $238.99 for the day. The stock traded down to $232.99 during the day, due to lack of any buying support eventually closed down at $233.00 with a loss of -1.85% for the day. The stock had closed at $237.39 on the previous day. The total traded volume was 1,955,884 shares.
Currently the company Insiders own 0.32% of Biogen shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -8.8% . Institutional Investors own 92.85% of Biogen shares. During last six month period, the net percent change held by insiders has seen a change of -7.26%. On the companys insider trading activities, Koppel Adam, officer (EVP, Strategy and Bus. Dev.) of Biogen Inc., unloaded 555 shares at an average price of $290 on June 6, 2016. The total amount of the transaction was worth $160,950, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.